Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enzyme-treated Ecklonia cava extract (EEc) is a phlorotannin-rich natural product derived from the brown seaweed *Ecklonia cava* through enzymatic processing with pectinase (Rapidase X-Press L) and cellulase (Rohament CL). This specific extraction method enhances the concentration of bioactive phlorotannins, including eckol, dieckol, and phlorofucofuroeckol-A, with dieckol being the most prominent constituent. EEc has been investigated in preclinical research for its anti-obesity and anti-adipogenic properties. It functions by modulating key transcription factors and signaling pathways involved in lipid metabolism, such as downregulating CCAAT/enhancer-binding protein alpha (C/EBPα), peroxisome proliferator-activated receptor gamma (PPARγ), and sterol regulatory element-binding protein-1c (SREBP-1c). Additionally, it activates AMP-activated protein kinase (AMPK) and increases the expression of adiponectin and glucose transporter type 4 (GLUT4), leading to reduced body weight and improved serum lipid profiles in animal models of high-fat diet-induced obesity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enzyme-treated ecklonia cava extract.